InterCure (INCR) Stock Price, News & Analysis

Company Overview

InterCure Ltd. (NASDAQ: INCR), also known as Canndoc, is an Israel-based cannabis company focused on the cultivation, production, distribution and sale of medical cannabis products. The company operates across the cannabis value chain, from growing and processing cannabis to supplying products through pharmacies and other regulated channels.

InterCure offers cannabis flower, oils and other medical cannabis products under its own brands and through international brand partnerships. Its portfolio has included the Cookies brand through a strategic partnership, along with products marketed under the Canndoc name. The company emphasizes pharmaceutical-grade production and compliance with applicable medical cannabis regulations.

Founded in Israel, InterCure has historically focused on the Israeli medical cannabis market while pursuing opportunities to expand its branded products and partnerships into additional regulated international markets. The company’s operations are conducted through subsidiaries and affiliated cannabis businesses, including Canndoc, and its shares trade on the Nasdaq and Tel Aviv Stock Exchange.

Key Stats

• Today's Range: $3.62 to $4.02
• 50-Day Range: $3.61 to $5.95
• 52-Week Range: $3.40 to $7.55
• Volume: 2,643 shs
• Average Volume: 13,614 shs
• Market Capitalization: $37.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

InterCure Stock Analysis - MarketRank™

InterCure scored higher than 9% of companies evaluated by MarketBeat, and ranked 846th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

InterCure has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

InterCure has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

InterCure has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the float of InterCure has been sold short.

Short Interest Ratio / Days to Cover

InterCure has a short interest ratio ("days to cover") of 0.98, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InterCure has recently decreased by 3.06%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InterCure does not currently pay a dividend.

Dividend Growth

InterCure does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InterCure insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.24% of the stock of InterCure is held by insiders.

Percentage Held by Institutions

8.34% of the stock of InterCure is held by institutions.

Company Calendar

• Today: 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:INCR
• CIK: 1857030
• Web: www.intercure.co
• Phone: 972774605012
• Fax: N/A
• Employees: 285
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $270.20 million
• Price / Sales: 0.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.53 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 10,936,000
• Free Float: 10,910,000
• Market Cap: $37.47 million
• Optionable: Optionable
• Beta: 1.50